Welcome to our dedicated page for Armata Pharmctcl news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmctcl stock.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) generates frequent news as a clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. News coverage of Armata often centers on its lead intravenous phage cocktail AP-SA02 for complicated Staphylococcus aureus bacteremia and its multi-phage candidate AP-PA02 targeting Pseudomonas aeruginosa in chronic respiratory disease.
Readers following ARMP news can expect detailed updates on clinical trial milestones, including topline data, late-breaking conference presentations, and regulatory interactions. Recent announcements have described positive Phase 1b/2a results from the diSArm study of AP-SA02, higher and earlier cure rates compared with antibiotics alone, and an End-of-Phase 2 written response from the U.S. Food and Drug Administration supporting advancement of AP-SA02 into a planned Phase 3 superiority study in complicated S. aureus bacteremia.
Armata’s news flow also includes information on manufacturing and infrastructure, such as the formal commissioning of its cGMP phage manufacturing facility in Los Angeles, California, which is intended to support late-stage clinical development and potential commercial production. Financial and corporate updates appear in quarterly results releases, describing grant and award revenue from the U.S. Department of Defense, secured credit agreements with Innoviva Strategic Opportunities LLC, and at-the-market equity offering arrangements.
Additional coverage highlights scientific publications and conference participation, including structural biology work on phage Pa223 in the Journal of Molecular Biology and presentations at IDWeek, the Military Health System Research Symposium, and the Evergreen Phage Meeting. For investors, clinicians, and researchers, this news page offers a centralized view of Armata’s progress in phage therapy, regulatory dialogue, funding developments, and manufacturing readiness. Bookmark this page to review ongoing ARMP press releases, SEC-linked disclosures, and other company communications as they are released.
Armata Pharmaceuticals (NYSE American: ARMP) reported fourth-quarter and full-year 2025 results for the period ended December 31, 2025. Key fourth-quarter figures include a net loss of $124.3 million (loss per share $(3.42)), cash and equivalents of $14.1 million, grant revenue of $1.1 million, and R&D expense of approximately $6.1 million.
The quarter included a $105.8 million non-cash fair-value loss on a convertible loan and a $5.4 million impairment on leased facilities. Debt maturities were extended to June 1, 2027 and Innoviva warrants were amended to expire January 26, 2031. Auditor included a going-concern explanatory paragraph.
Armata Pharmaceuticals (NYSE American: ARMP) delayed its Q4 and full‑year 2025 financial results and expects to file its Form 10‑K on or before March 31, 2026. The company received QIDP designation for AP‑SA02 and completed an End‑of‑Phase 2 response enabling a planned Phase 3 superiority trial anticipated to start in H2 2026. Armata commissioned a 56,000 sq ft cGMP facility in Los Angeles with full production runs completed. Phase 2a diSArm data presented at IDWeek 2025 showed higher early cure rates and favorable tolerability for AP‑SA02 versus BAT.
Armata Pharmaceuticals (NYSE: ARMP) announced that the FDA granted QIDP designation to AP-SA02 for intravenous adjunct treatment of complicated bacteremia caused by MSSA or MRSA on February 23, 2026. The designation makes AP-SA02 eligible for five additional years of Hatch-Waxman market exclusivity and potential Fast Track, priority and rolling review. Armata plans to request Fast Track and to initiate a Phase 3 superiority study in H2 2026.
Armata Pharmaceuticals (NYSE: ARMP) received an End-of-Phase 2 written response from the FDA and the agency agreed that data from Armata's Phase 2a diSArm study support advancing AP-SA02 into a Phase 3 superiority study in complicated Staphylococcus aureus bacteremia. The company plans to initiate the Phase 3 study in the second half of 2026 and is addressing FDA comments on CMC, clinical design, and BLA recommendations. Armata has submitted a request for QIDP designation and highlighted Phase 2a results announced in May 2025 and presented at IDWeek 2025.
Armata Pharmaceuticals (NYSE: ARMP) received an End-of-Phase 2 written response from the FDA confirming that safety and efficacy data from its Phase 2a diSArm study support advancing IV AP-SA02 into a Phase 3 superiority study for complicated Staphylococcus aureus bacteremia. The Phase 3 trial is anticipated to initiate in the second half of 2026 and will test AP-SA02’s superiority versus standard of care, with primary endpoints at end of best available antibiotic therapy and at Day 28. The FDA provided guidance on study design, CMC, BLA expectations, and encouraged a QIDP request; Armata has submitted a QIDP request and is addressing FDA comments.
Armata Pharmaceuticals (NYSE American: ARMP) will host a KOL webinar on November 25, 2025 at 10:00am EST featuring Dr. Vance G. Fowler Jr. on complicated S. aureus bacteremia and Armata's phage therapy AP-SA02.
The company highlighted positive Phase 1b/2a diSArm results presented at IDWeek 2025 showing AP-SA02 plus best available antibiotic therapy produced a higher, earlier cure rate at Test of Cure and a 100% response without relapse at TOC and 28 days later (EOS) versus ~25% lack of response/relapse for placebo plus BAT. AP-SA02 was reported well-tolerated with efficacy against MRSA and MSSA.
Armata Pharmaceuticals (NYSE: ARMP) reported Q3 2025 results and a corporate update on November 12, 2025. Key clinical news: Phase 1b/2a AP-SA02 (IV) for complicated Staphylococcus aureus bacteremia showed higher and earlier cure at day 12 versus placebo+BAT, with a 100% response without relapse at one week and day 28 in the AP-SA02 arm versus ~25% nonresponse/relapse in placebo. AP-SA02 was well tolerated and shortened time to negative blood culture and hospital utilization. Operationally, Armata commissioned its Los Angeles cGMP facility and closed a $15.0M secured loan; unrestricted cash was $14.8M as of Sept 30, 2025.
Armata Pharmaceuticals (NYSE American: ARMP) announced formal commissioning of its new cGMP phage manufacturing facility in Los Angeles on November 10, 2025. The 56,000 sq ft site includes 10,000 sq ft of cGMP clean rooms, an automated fill-and-finish suite, quality control and R&D labs, and administrative space. The company notified the FDA that production has commenced and completed full production runs with no issues. The facility is positioned to supply high-purity multi-phage cocktails for clinical programs and to support a potential Phase 3 AP-SA02 trial planned for 2026, subject to FDA review, plus future commercial and contract manufacturing opportunities.
Armata Pharmaceuticals (NYSE American: ARMP) reported positive Phase 2a diSArm results for IV bacteriophage cocktail AP-SA02 in complicated Staphylococcus aureus bacteremia, presented at IDWeek 2025 on Oct 22, 2025. The randomized, double-blind trial enrolled 42 patients (29 AP-SA02 + BAT; 13 placebo + BAT).
Day 12 clinical response: 88% vs 58% (PI assessment, p=0.047); adjudicator assessment 83% vs 58%. Non-response/relapse at one week post-BAT and at EOS: 0% AP-SA02 vs ~25% placebo (p-values 0.017–0.025). AP-SA02 was well tolerated; no serious adverse events related to drug. Armata plans a Phase 3 superiority trial in 2026, subject to FDA feedback.
Armata Pharmaceuticals (NYSE American: ARMP) will present late-breaking Phase 2a clinical data on its Staphylococcus aureus bacteriophage cocktail AP-SA02 at IDWeek 2025 in Atlanta, GA.
The oral presentation, titled "A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus aureus Bacteremia," will be given by Dr. Loren G. Miller on Wednesday, October 22, 2025, from 10:30 AM to 11:45 AM ET in room B401-B402 during the session "Late Breaking Info That May Change Your Approach To Bacterial and Fungal Infections."